Risk factors
Dyadic International (DYAI) risk factors
Item 1A of every Dyadic International Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks3 new10 dropped14 reworded
Dyadic is transitioning from a research-driven firm to a commercially focused enterprise commercializing C1 and Dapibus technologies. The company faces extensive regulatory requirements from the FDA, EMA, and other authorities governing pharmaceutical development. Global economic conditions and capital constraints threaten Dyadic's ability to fund operations and execute its strategy.
Filed Mar 25, 2026 - FY2024 10-K risk factors54 risks
Dyadic's risks are dominated by early-stage biotechnology development uncertainties, reliance on collaborative partnerships, and limited customer concentration.
Filed Mar 26, 2025